Singapore markets open in 8 hours 48 minutes
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,972.13 -5.40 (-0.14%) Dow
32,493.71 +61.63 (+0.19%) Nasdaq
11,695.29 -73.54 (-0.62%) Bitcoin USD
26,921.15 -249.67 (-0.92%) CMC Crypto 200
589.68 +347.00 (+142.99%)
AZN Oct 2023 45.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:41AM EDT. Market open.
| Previous close | 0.4000 |
| Open | 0.3800 |
| Bid | 0.2900 |
| Ask | 0.6600 |
| Strike | 45.00 |
| Expiry date | 2023-10-20 |
| Day's range | 0.3800 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
